No registrations found.
ID
Source
Brief title
Health condition
Healthy population
Food allergies (Voedselallergie)
Intestinal permeability (Darmdoorlaatbaarheid)
Detection method development for dietary protein in blood (Ontwikkeling detectivemethode voor voedingseiwit in bloed)
Sponsors and support
Wageningen University and Research Centre (IPOP Customized Nutrition)
Intervention
Outcome measures
Primary outcome
The main study outcome is the number of subjects in which Ara h6 can be detected in serum over time following peanut consumption with a sandwich ELISA.
Secondary outcome
The secondary outcome is sensitivity of the sandwich ELISA after further optimization
Background summary
In this pilot study 10 healthy, normal weight male and female participants will be tested for their serum peanut protein (Ara h6) levels after intake of 100 grams of roasted peanuts. A sandwich ELISA will be developed and optimized to be able to detect Ara h6 in as many participants as possible at low detection levels.
Study objective
In order to support allergy research, well-defined and validated methods for measuring allergens are needed. Currently, there is no such method sensitive enough to detect Ara h6 in the circulation after peanut consumption. Therefore, developing this method would be a valuable tool in the field of food allergies.
Study design
Ara h6 will be analysed in serum sampled at baseline and 30, 60, 120, 240, and 360 min after peanut intake.
Intervention
Intake of 100grams of roasted peanuts.
Blood sampling via venflon cannula at baseline and 30, 60, 120, 240, and 360 min after peanut intake.
Lonneke Janssen Duijghuijsen
P.O. Box 17
Wageningen 6700 AA
The Netherlands
0317-482643
lonneke.janssen@wur.nl
Lonneke Janssen Duijghuijsen
P.O. Box 17
Wageningen 6700 AA
The Netherlands
0317-482643
lonneke.janssen@wur.nl
Inclusion criteria
- 20-35 year old males and females
- Body mass index (BMI) 18.5-25 k- Suitable veins for blood sampling
Exclusion criteria
- History of peanut allergy
- Known symptoms of immune disease, such as diabetes, gastritis, and coeliac disease.
- Known symptoms of intestinal disease, such as Crohn’s Disease, ulcerative colitis, and irritable bowel syndrome.
- Smoking
- Use of hard drugs
- Use of specific medicines:
- Chronic use of NSAIDs: aspirins, ibuprofen, etc.
- Drugs having an effect on gastric and/or intestinal function and motility, including antidepressants.
- Participation in other scientific studies
- Blood donation during the last six weeks before the start of the study
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4848 |
| NTR-old | NTR5655 |
| Other | METC Wageningen University : 15/34 |